16 Result(s)

Article

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose...

H Goldschmidt, H M Lokhorst, E K Mai, B van der Holt, I W Blau, S Zweegman… in Leukemia (2018)

Article

Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality—a single institution experience

Allogeneic stem cell transplantation is a treatment option for patients with poor risk CLL. We conducted a retrospective analysis of all CLL patients allografted at our institution, the University Hospital of ...

G. Chakupurakal, S. Leitzke, P. Langerbeins, J. Schiller… in Annals of Hematology (2015)

Article

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality...

R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, S K Metzelder… in Leukemia (2015)

Article

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response ...

E K Mai, U Bertsch, J Dürig, C Kunz, M Haenel, I W Blau, M Munder, A Jauch… in Leukemia (2015)

Article

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have gained interest. The randomized CML ...

L Kalmanti, S Saussele, M Lauseker, M C Müller, C T Dietz, L Heinrich… in Leukemia (2015)

Article

Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy

S Tuve, J Gayoso, C Scheid, J Radke, A Kiani, D Serrano, U Platzbecker… in Leukemia (2011)

Article

Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea

The optimum treatment conditions of interferon (IFN) α therapy in chronic myeloid leukemia (CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN therapy, we conducted a ra...

R Hehlmann, U Berger, M Pfirrmann, A Hochhaus, G Metzgeroth, O Maywald… in Leukemia (2003)

Article

Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) mobilized peripheral blood progenitor cells (PBPCs) from healthy individuals are a rapidly emerging alternative source to bone marrow for allo...

D. Beelen, H. Ottinger, K. Kolbe, W. Pönisch, H. Sayer, W. Knauf… in Annals of Hematology (2002)

Article

Fatal thrombotic thrombocytopenic purpura as a rare complication following allogeneic stem cell transplantation

 Thrombotic thrombocytopenic purpura (TTP) is a rare disease which, together with hemolytic uremic syndrome, is subsumed under thrombotic microangiopathy. After stem cell transplantation (SCT), this syndrome r...

J. Chemnitz, M. Fuchs, W. Blau, P. Hartmann, C. Wickenhauser… in Annals of Hematology (2000)

Article

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML

 The current phase-II trial was initiated to assess the efficacy and toxicity of the Ida-FLAG regimen in patients with poor-risk acute myeloid leukemia (AML). Three subgroups of patients with AML were eligible...

H. T. Steinmetz, A. Schulz, P. Staib, C. Scheid, A. Glasmacher… in Annals of Hematology (1999)

Article

A case of thrombotic thrombocytopenic purpura in an adult treated with vincristine

 The case of a woman with thrombotic thrombocytopenic purpura refractory to prolonged treatment with plasma exchange and steroid treatment is described. The addition of vincristine yielded a complete response,...

A. Schulz, G. Sitzler, C. Scheid, H. J. Deutsch, J. Chemnitz… in Annals of Hematology (1999)

Chapter and Conference Paper

Lack of Correlation Between Multi-Drug Resistance Expression and Clinical Response to Chemotherapy in Patients with Acute Myeloid Leukemia

Expression of the multi-drug-resistance (MDR) protein gpl70 encoded by the mdrl gene has been implied to play a role in acute myeloid leukemia (AML) refractory to chemotherapy. We investigated MDR expression b...

A. Schulz, P. Engling, Q. Cao, C. Scheid, V. Diehl… in Acute Leukemias VI (1997)

Article

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion

Bryostatin 1 is a macrocyclic lactone derived from the marine invertebrate Bugula neritina. In vitro, bryostatin 1 activates protein kinase C (PKC), induces the differentiation of a number of cancer cell linea...

GC Jayson, D Crowther, J Prendiville, AT McGown, C Scheid… in British Journal of Cancer (1995)

Article

Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity

Interleukin-6 (IL-6) is a cytokine that acts on a variety of cell types, including myeloid progenitor cells and B and T lymphocytes. It has been found to activate cytotoxic T cells and natural killer (NK) cell...

C. Scheid, R. Young, R. McDermott, L. Fitzsimmons… in Cancer Immunology, Immunotherapy (1994)